Michael Ulz
Stock Analyst at Morgan Stanley
(4.10)
# 470
Out of 4,918 analysts
103
Total ratings
49.21%
Success rate
15.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $312 → $405 | $401.80 | +0.80% | 11 | Aug 1, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $55 → $62 | $43.03 | +44.09% | 5 | Jul 31, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $54 → $42 | $3.95 | +963.29% | 6 | May 13, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.14 | +307.17% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $32.68 | +212.12% | 3 | Apr 24, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $3.42 | +484.80% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.44 | +1,427.78% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $12.18 | +138.10% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.53 | +54.53% | 7 | Mar 5, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.68 | +646.27% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.81 | +452.49% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $48.37 | +98.47% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $10.05 | +417.41% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $52.02 | +9.57% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $15.93 | +69.49% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.07 | +554.21% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.13 | +166.67% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.68 | +1,090.48% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $2.99 | +1,405.02% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.65 | +1,438.46% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.63 | +14.07% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.03 | +497.01% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.32 | +2,181.37% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $10.10 | +345.77% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $6.60 | +203.03% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $28.44 | +181.29% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $6.32 | +137.53% | 3 | Jul 12, 2017 |
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $312 → $405
Current: $401.80
Upside: +0.80%
Ionis Pharmaceuticals
Jul 31, 2025
Upgrades: Overweight
Price Target: $55 → $62
Current: $43.03
Upside: +44.09%
Karyopharm Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $54 → $42
Current: $3.95
Upside: +963.29%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.14
Upside: +307.17%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $32.68
Upside: +212.12%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $3.42
Upside: +484.80%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.44
Upside: +1,427.78%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $12.18
Upside: +138.10%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.53
Upside: +54.53%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.68
Upside: +646.27%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.81
Upside: +452.49%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $48.37
Upside: +98.47%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $10.05
Upside: +417.41%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $52.02
Upside: +9.57%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $15.93
Upside: +69.49%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.07
Upside: +554.21%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.13
Upside: +166.67%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.68
Upside: +1,090.48%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $2.99
Upside: +1,405.02%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.65
Upside: +1,438.46%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.63
Upside: +14.07%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.03
Upside: +497.01%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.32
Upside: +2,181.37%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $10.10
Upside: +345.77%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $6.60
Upside: +203.03%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $28.44
Upside: +181.29%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $6.32
Upside: +137.53%